Since TGF-β signaling is recognized to drive the epithelial-mesenchymal transition and liver fibrosis progression toward advanced liver cancer, many drugs targeting TGF-β signaling in liver cancers are currently under investigation in clinical trials [51]. The gene discussed is TGFB1; the disease is liver cancer.